GLP-1s Show Anti-Inflammatory Effects in Osteoarthritis Independent of Weight Loss — New Cell Metabolism Study

GLP-1s Show Anti-Inflammatory Effects in Osteoarthritis Independent of Weight Loss — New Cell Metabolism Study

In addition to cellular-level anti-inflammatory findings, robust real-world clinical evidence has emerged demonstrating that long-term GLP-1 receptor agonist use significantly reduces the risk of knee replacement surgery in patients with osteoarthritis (OA).¹

A massive retrospective cohort study published in Regional Anesthesia & Pain Medicine (June 2, 2026) by researchers at the University of Maryland School of Medicine analyzed data from 6.8 million adults diagnosed with knee osteoarthritis between 2010 and 2024. Using propensity score matching, they compared patients taking GLP-1s with matched controls who were not.

Key Clinical Findings

• 1-Year GLP-1 Use: Associated with a 1.4-percentage-point reduced risk of knee replacement surgery at 3 years, and a 2.8-percentage-point lower risk after 8 years.
• 3-Year Semaglutide or Tirzepatide Use: Associated with a nearly 5-percentage-point lower chance of undergoing knee replacement at the 8-year follow-up.
• Public Health Impact: Researchers estimate that if all eligible patients with knee OA and obesity or metabolic syndrome took semaglutide or tirzepatide for three years, it could prevent up to 14,400 knee replacements annually in the US and over 1,500 in the UK.

Underlying Mechanisms

The therapeutic benefit is believed to be dual-action:

1. Mechanical Relief: Significant body weight reduction directly lowers the mechanical load and wear-and-tear on weight-bearing joints like the knees and hips.
2. Biological Protection: Direct anti-inflammatory, analgesic, and potentially cartilage-protective effects of GLP-1 receptor agonists that operate through weight-independent pathways, as supported by preclinical cellular models showing reduced cartilage destruction and osteophyte formation.

This real-world data further expands the clinical utility of GLP-1s, moving them closer to becoming standard chronic therapies for managing severe osteoarthritis and joint pain, which represents a massive expansion of their total addressable market (TAM).